Published in Blood Weekly, May 30th, 2002
Last month, ISTA announced the preliminary safety and efficacy results for two phase III clinical trials of a single injection of Vitrase for the treatment of severe vitreous hemorrhage. The company subsequently provided the FDA with preliminary study data analysis and has held discussions with the FDA regarding the analysis noting the improvement in visual function as measured by visual...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.